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BRCA2, the second hereditary breast cancer gene, has been
mapped to chromosome 13q12–13 (Wooster et al, 1994). BRCA2
is a very large gene spanning more than 70 kb of genomic DNA
encoding 3495 amino acids (Wooster et al, 1995; Tavtigian et al,
1996). To date more than 300 distinct germline mutations of
BRCA2 (http://www.nhgri.nih.gov/intramural_ research/lab_trans-
fers/bic) have been identified that predispose carriers to breast
cancer and to a lesser extent ovarian cancer (Rahman and Stratton,
1998). A small increase in risk for pancreatic and prostate cancer
has also been reported in BRCA2 pedigrees (Wooster et al, 1995;
Lancaster et al, 1996; Phelan et al, 1996). Frequent loss of
heterozygosity (LOH) at the BRCA2 locus in a variety of sporadic
cancers e.g. breast, ovarian (Lancaster et al, 1996), pancreatic,
prostate (Cooney et al, 1996; Li et al, 1998), hepatocellular cancer
(Kuroki et al, 1995), suggests this gene may behave as a tumour
suppressor gene (Cleton-Jansen et al, 1995). However, no clear
disease-causing somatic mutations have been described in BRCA2
in sporadic breast cancers, and somatic mutations in ovarian
cancers are very rare (Foster et al, 1996; Lancaster et al, 1996;
Miki et al, 1996; Takahashi et al, 1996; Teng et al, 1996). The lack
of somatic BRCA2 mutations in sporadic breast and ovarian
cancers could be due to the mutation detection assays used.
Mutations may be missed if they are outside of the region of
analysis and certain types of mutations (large deletions, insertions
and duplications) may not be detected by PCR-based mutation
detection assays. Southern blot analyses have identified 5 large
Alu-mediated genomic deletions (Petrij-Bosch et al, 1997; Puget
et al, 1997b; Swensen et al, 1997) and a 6 kb Alu-mediated du-
plication (Puget et al, 1997a) involving BRCA1 in breast cancer
families that would have been missed by conventional PCR-based
mutation screening methods such as SSCP, PTT or direct
sequencing using genomic DNA as template. A recent study found
one case of sporadic breast cancer out of 81 studied with BRCA1
genomic deletions (van der Looij et al, 2000). Similar large
genomic deletions have also been described in other tumour
suppressor genes e.g. p53 (Masuda et al, 1987; Ruggeri et al,
1992),  hMLH1 (Nystrom-Lahti et al, 1995), hMSH2 (Wijnen et al,
1998) and Rb-1 (Ruggeri et al, 1992). Thus, we wanted to invest-
igate whether similar genomic deletions occur in BRCA2 which
may have escaped detection using PCR-based techniques. 
MATERIALS AND METHODS 
We undertook Southern blot analysis of genomic DNA in a large
series of 130 invasive breast tumours comprising ductal, lobular,
mucinous, tubular, cribriform and squamous cell metaplastic carcin-
omas. These tumours were snap frozen at the point of collection.
Genomic DNA from these primary tumours was digested with
EcoRI. In addition, genomic DNA from established cell lines
derived from breast (39), ovarian (29), pancreatic (7) and small
cell lung (SCLC) tumours (8) was digested with 4 different restric-
tion endonucleases (BamHI, EcoRI, HindIII and PstI). Digested
DNA was size fractionated by electrophoresis and transferred onto
nylon membranes. Filters were hybridized separately with two
clones containing BRCA2 cDNA. The first is a 5.8 kb fragment
representing amino acids 1–1963 (BRCA2-front) and the second
fragment is 4.6 kb from amino acids 1895–3495 (BRCA2-back). 
RESULTS 
Initially, we detected aberrant-sized fragments in two primary
tumours; tumour 386 with both probes and tumour 64 NT with
BRCA2-front probe (Figure 1). There were 8 breast cancer cell
lines that showed restriction fragment size fragment abnormalities
with BRCA2-front and 4 with BRCA2-back. In ovarian cancer cell
lines, abnormalities were only observed in 3 cell lines using
BRCA2-front. No abnormalities were detected in any of the SCLC
or pancreatic cell lines. A representative sample of these Southern
blot experiments is presented in Figure 1. 
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normal samples, the experiments were repeated with longer in-
cubation of the DNA with the respective restriction endonucleases
to ensure complete digestion. No abnormal restriction fragments
were detected in any of the samples suggesting that the initial
abnormal bands were due to incomplete digestion (data not
shown). While no large genomic deletions were observed in the
BRCA2 gene, restriction fragment length polymorphisms were
observed in both primary tumours and cell lines (Figure 2). 
DISCUSSION 
In summary, BRCA2 does not undergo large intragenic deletions in
human tumours. Only 8 somatic BRCA2 mutations, 3 in breast
tumours (Lancaster et al, 1996; Miki et al, 1996; Weber et al, 1996),
4 in ovarian cancers (Foster et al, 1996; Takahashi et al, 1996) and
one in a hepatocellular carcinoma (Katagiri et al, 1996), have been
reported since the discovery of the gene using PCR-based mutation
detection assays. Similar to BRCA1, the region containing BRCA2
undergoes loss of heterozygosity in a fraction of breast and ovarian
tumours (Cleton-Jansen et al, 1995). In fact in another study using
these cell lines, we found that 24/36 breast (67%), 6/30 ovarian
(20%), 4/7 pancreatic (57%) and 5/8 SCLC (63%) used in this study
had homozygosity for all markers tested in the region encompassing
BRCA2 (data not shown) suggestive of allelic deletions. Partial
mutational analyis of BRCA2 mutations was undertaken for some of
the cell lines with LOH and to date, only one breast cancer cell line
with LOH, MT-3, was found to have a 1 bp deletion in exon 23 of
BRCA2 (KL Gorringe & C Caldas, unpublished data). Like BRCA1,
the lack of BRCA2 mutations in sporadic breast and ovarian cancers
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Figure 1 Southern analysis of BRCA2 gene in primary breast tumours (328, 378, 386, 64NT), breast cancer cell line (MT-3), and ovarian cancer cell lines
(OVISE, KEN-3) digested with EcoRI. Hybridization with (A) BRCA2-front and (B) BRCA2-back shows aberrant restriction fragments
Figure 2 Restriction fragment length polymorphism seen in the normal
control, breast (BT-549) and ovarian cancer cell lines digested with Pst-1 and
hybridized with BRCA2-front
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9suggest either distinct genetic pathways or different mechanisms for
inactivating gene function compared to the familial forms (Rahman
and Stratton, 1998). The high frequency of LOH on chromosome
13q could be explained by the close proximity of other tumour
suppressor genes e.g. retinoblastoma (Lee et al, 1988), Brush-1
(Schott et al, 1994) or other putative tumour suppressor gene(s) that
might be targeted instead of BRCA2. 
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